𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recent Developments in Hematopoietic Stem Cell Transplantation for Multiple Myeloma

✍ Scribed by William I. Bensinger

Publisher
Carden Jennings Publishing
Year
2003
Tongue
English
Weight
101 KB
Volume
77
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Predictors of prolonged survival after a
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
✍ Qaiser Bashir; Hassan Khan; Robert Z. Orlowski; Ali Imran Amjad; Nina Shah; Simr πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 746 KB

## Abstract A total of 149 patients with multiple myeloma (MM) who received allogeneic hematopoietic stem cell transplantation (allo‐HCT) with myeloablative (MAC; __n__ = 38) or reduced‐intensity conditioning (RIC; __n__ = 110) regimens at MD Anderson Cancer Center were evaluated. Of the total, 120

The role of stem cell transplantation in
The role of stem cell transplantation in multiple myeloma
✍ Jean-Luc Harousseau; Michel Attal πŸ“‚ Article πŸ“… 2002 πŸ› Elsevier Science 🌐 English βš– 193 KB

High-dose therapy with autologous stem cell transplantation (ASCT) has been extensively used in the past 15 years in multiple myeloma. The IFM 90 trial has shown that autologous bone marrow transplantation (BMT) is superior to conventional chemotherapy in terms of response rate, event free survival,

Symptom burden after autologous stem cel
Symptom burden after autologous stem cell transplantation for multiple myeloma
✍ Erica Campagnaro; Rima Saliba; Sergio Giralt; Linda Roden; Floralyn Mendoza; Ana πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 106 KB

## Abstract ## BACKGROUND Multiple myeloma (MM) is the most common indication for high‐dose chemotherapy with autologous stem cell transplantation (ASCT) in the U.S. and can be associated with substantial morbidity. Thorough assessment and understanding of symptoms and risk factors for symptom dev